<DOC>
	<DOCNO>NCT01817374</DOCNO>
	<brief_summary>1 . Evaluate quantitative VCEUS image determine early breast cancer response neoadjuvant chemotherapy compare result co-temporal volume change grayscale ultrasound post-treatment mammography finding utilize final surgical pathology clinical outcome . 2 . Assess incremental benefit quantitative VCEUS planar CEUS tumor perfusion measurement enhancement pattern predict tumor response adjuvant treatment clinical study . The contrast agent Definity® FDA approve use contrast agent ultrasound ( echocardiography ) heart . Definity® use `` off-label '' ( ultrasound breast ) study . The administration Definity® study follow total dose guideline approve FDA .</brief_summary>
	<brief_title>Breast VCEUS Evaluate Early Response Neoadjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Adult patient ( age 19 year old ) . 2 . Patients newly diagnose untreated stage II III breast cancer schedule undergo neoadjuvant chemotherapy . 3 . Patients sign informed consent . 1 . Any history prior radiation chemotherapy breast cancer . 2 . Patients nonmeasurable disease . 3 . Patients medically unstable . 4 . Patients primary cancer require systemic treatment . 5 . Patients cardiac shunt . 6 . Patients unstable cardiopulmonary condition . 7 . Patients know pulmonary hypertension . 8 . Patients know hypersensitivity component Definity ( R ) microbubble contrast . 9 . Patients pregnant , breastfeed plan become pregnant study duration .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Definity</keyword>
	<keyword>Ultrasound</keyword>
</DOC>